GLP1减重宝典·2025-12-10 14:14Core Viewpoint - The article discusses the global licensing agreement between Fosun Pharma's subsidiary, Yaoyou Pharmaceutical, and Pfizer for the oral GLP-1 receptor agonist project, YP05002, which aims to treat metabolic diseases including type 2 diabetes and obesity [5][7]. Group 1: Licensing Agreement Details - Fosun Pharma's Yaoyou Pharmaceutical has signed a global licensing agreement with Pfizer, granting exclusive rights for the development, production, and commercialization of YP05002 and related products [5]. - Under the agreement, Yaoyou Pharmaceutical will receive an upfront payment of $150 million and has the potential to earn up to $350 million in milestone payments based on project progress [5]. - If the product meets commercial sales targets, Pfizer will pay Yaoyou Pharmaceutical up to $1.585 billion in sales milestone payments [5]. Group 2: Product Overview - YP05002 is an oral small molecule GLP-1 receptor agonist developed by Fosun Pharma, designed to activate GLP-1 receptors to promote insulin secretion, suppress glucagon secretion, delay gastric emptying, and reduce energy intake [7]. - The candidate drug is primarily aimed at treating metabolic diseases, with potential indications including long-term weight management, type 2 diabetes, and non-alcoholic fatty liver disease [7]. - Currently, YP05002 is undergoing Phase I clinical trials in Australia [7].